M1412 – Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

Long description

Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

Short description

Met nsclc w/ egfr alk oth ab

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

Z2 Undefined codes

Added

January 1, 2025

Last change

January 1, 2025 – No change

Nearby M codes

• M1404 – Patients on a therapeutic clinical trial
• M1405 – Patients with recurrence/disease progression
• M1406 – Patients who leave the practice during the follow-up period
• M1407 – Patients who died during the follow-up period
• M1408 – Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
• M1409 – Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
• M1410 – Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
• M1411 – Currently on first-line immune checkpoint inhibitors without chemotherapy
• M1413 – Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
• M1414 – Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is in an urgent or emergent situation where delay of treatment would jeopardize the patient's health status; other medical reasons/contraindication)
• M1415 – Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy
• M1416 – Patient received hospice services any time during the performance period
• M1417 – Patients who are up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination
• M1418 – Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination because of a medical contraindication documented by clinician
• M1419 – Patients who are not up to date on their covid-19 vaccinations as defined by cdc recommendations on current vaccination
• M1420 – Complete ophthalmologic care mips value pathway